Aim: This study investigated the efficacy and safety of perampanel (PER) adjunctive therapy in pediatric patients with epilepsy whose seizures are pharmacoresistant to existing antiepileptic drugs. Methods: A clinical retrospective study was conducted from 2016 to 2017 in the pediatric neurology clinic at a tertiary children's hospital. We reviewed the data obtained from 66 children whose seizures were pharmacoresistant to more than two antiepileptic drugs, and could be followed up for a minimum of 3 months after PER adjunctive therapy initiation. The efficacy was estimated by the PER response rate at 3-, 6-, and 12-month follow-up evaluations, and adverse events were also recorded. Results: The rate of seizure reduction of N 50% was 30.3%, 37.5%, and 34.7% for all seizure types at 3, 6, and 12 months, in which 7.6%, 8.9%, and 14.3% of the patients became seizure-free at these time points, respectively. No significant differences were found between enzyme-inducing and nonenzyme-inducing antiepileptic drugs in combination with PER with regard to the responder rate. Five patients with Dravet syndrome were included in the study. Four of them (80%) exhibited 50% seizure reduction at the last visit, at which point, two patients (40.0%) were seizure-free. The retention rate was 51% at 12 months. Adverse events were documented in 25 patients (35.7%) and led to PER discontinuation in eight patients (12.1%). The most common adverse events comprised irritability, skin rash, dizziness, and somnolence; however, all were transient and successfully managed after PER dose reduction or discontinuation. Conclusion: The current data support the value of adjunctive PER in child and adolescent patients with pharmacoresistant epilepsy in daily clinical practice. Perampanel was efficacious and generally well-tolerated as an add-on treatment for epilepsy.
Introduction
Children with pharmacoresistant epilepsy are at a considerable risk of cognitive impairment, behavioral and mental health problems, and overall compromised quality of life [1] [2] [3] . Early seizure control in these patients is crucial. Activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, a member of the ionotropic class of glutamate receptors, mediates the overwhelming majority of fast excitatory synaptic transmission throughout the central nervous system and is crucial for various high cognitive functions, including learning and memory, and synaptic plasticity, thus indicating its physiological importance [4] [5] [6] . Findings of previous studies confirmed that overactivation of AMPA receptors is highly neurotoxic [7] [8] [9] and indicated its pathophysiological role in generation and spread of epileptic seizures [6, [10] [11] [12] [13] [14] . In addition, hyperactivity induced by seizures has been suggested to alter posttranscriptional AMPA receptor splicing, which critically determines receptor desensitization and thus the duration of excitation [15] [16] [17] [18] .
Among the novel antiepileptic drugs, perampanel (PER) is a first-inclass, highly selective, noncompetitive antagonist of the AMPA glutamate receptor [6, 19] . Perampanel has been widely licensed and approved for adjunctive treatment of focal seizures, with or without secondarily generalized seizures, and for primary generalized tonicclonic seizures in patients with epilepsy aged ≥ 12 years [20, 21] . The Epilepsy & Behavior xxx (2018) xxx-xxx efficacy and safety, including that for cognitive function, of PER in children aged ≥12 years have been demonstrated in the subgroup analysis of three randomized controlled trials and a combined extension study, the results of which were similar to data derived from adult population [22] [23] [24] . Another randomized study confirmed that adjunctive PER is efficacious and well-tolerated in adolescents with focal-onset seizures, and appears to have no clinically important impact on behavior measured using the Child Behavior Checklist [25] . A few observational studies of the use of PER in children and adolescents have been reported in the last 3 years. Data from these real-world clinical experiences, although comprising heterogeneous groups of patients, also indicated that PER was reasonably effective in pediatric patients with refractory epilepsy or with severe epileptic encephalopathies and generally with a well-tolerability profile [26] [27] [28] [29] [30] .
However, clinical data on the tolerability and efficacy of PER are limited in real-world clinical settings involving Asian children. Considering that race/ethnicity may account for the differences in the pharmacokinetics and pharmacodynamics of drugs, the response of PER in Asian patients with respect to safety, efficacy, and the resulting differences in recommended doses should be carefully evaluated. In the present study, we aimed to describe our experience with PER adjunctive treatment in Asian children and adolescents with refractory epilepsy.
Materials and methods

Patients
We retrospectively identified patients with epilepsy aged ≤18 years who received PER as adjunctive therapy between January 2016 and September 2017 in the Department of Pediatric Neurology, Chang Gung Children's Hospital, Taiwan. Only those patients with a minimum follow-up period of 3 months were eligible. Patients who were intermittently nonadherent to their drug regimen or had poor clinical attendance and those who did not appropriately document their seizure frequencies and descriptions were excluded. The hospital's Institutional Review Board approved this study (201701598B0).
Collected data
Patient data regarding demographics, etiology, seizure types, epilepsy syndrome, epilepsy duration before treatment with PER, previous and concomitant antiepileptic drugs, highest dosage of PER, seizure frequency before and after treatment initiation, and reasons for PER discontinuation were documented from the medical records. Data on seizure frequency and types were also obtained from self-reported seizure diaries that were maintained by patients or families. Seizure types and epilepsy syndromes were classified based on criteria of the International League Against Epilepsy (ILAE).
Efficacy, which was accessed by the responder rate, was evaluated by comparing the frequency of seizures in the 4 weeks before PER application and after the maximal dosage of PER was achieved. The responder rate was defined as the number of patients whose seizure frequency in the last three months was reduced by ≥50% compared with the baseline mean seizures frequency. Seizure freedom was defined as no seizures during the previous three months. Tolerability was assessed via the documentation of possible adverse effects during treatment. Information regarding adverse events was recorded according to reports from the patients themselves or their caregivers.
Data analysis
Inferential statistical tests were used to describe the mean and standard deviation of the quantitative variables (with normal distribution) and median (without normal distribution), and percentages for the qualitative variables. A regression analysis (correlation) was used for the statistical analysis of between-group differences of continuous variables, and the chi-squared test was used for categorical variables. Adverse events were reported throughout the study. SPSS Version 21 (SPSS, Chicago, IL, USA) was performed for all data analysis.
Results
Demographic and baseline characteristics of patients
A total of 70 children and adolescents aged ≤18 years who experienced pharmacoresistant epilepsy and underwent treatment with PER as adjunctive therapy were identified. Among these, four patients were excluded from the study as one patient had poor compliance and another three provided incomplete data (n = 3). In total, 66 pediatric patients were included in the analysis (32 females; aged 8-18 years, mean: 14.9 ± 2.3 years). All patients had complete data from ≥ 3 months follow-up available for analysis. A flowchart of patient numbers and retention rates at 3-, 6-, and 12-month follow-up is presented in Fig. 1 . Baseline demographic and clinical data according to age groups are summarized in Table 1 . The mean age at onset of epilepsy was 4.9 ± 3.9 years. The mean duration of epilepsy was 10.3 ± 4.4 years. Most patients experienced focal-onset seizures; the most frequently reported dominant seizure types were focal to bilateral tonic-clonic (43.9%), focal only (31.8%), generalized onset tonic-clonic (6.1%), and others (such as absences, myoclonic seizures, infantile spasms; 4.5%) as well as unknown in nine patients (13.6%) ( Table 1 ). The epilepsy syndrome and etiology are described in Supplemental Table 1 in detail, including Lennox-Gastaut syndrome (n = 6, 9.1%), Dravet syndrome (n = 5, 7.6%), juvenile myoclonic epilepsy (n = 3, 4.5%), and progressive myoclonic epilepsy (n = 1, 1.5%).
Dosage and treatment
At the time of PER treatment initiation, all patients received antiepileptic drugs. The median of other concomitant antiepileptic drugs used in combined therapy with PER was three (range: 1-7). Patients had previously exhibited resistance to a mean of 6.2 ± 2.8 (median: 6, range: 2-15) previous antiepileptic drugs and fulfilled the criteria for pharmacoresistant epilepsy. Concomitant antiepileptic therapy was continued or gradually reduced during the observation period. A total of 28 (42.4%) patients were taking enzyme-inducing antiepileptic drugs, and of these, the most frequently taken was oxcarbazepine (n = 28, 41.4%), followed by carbamazepine (n = 2, 2.9%) ( Table 1) .
Add-on therapy with PER was typically initiated at a dose of 1-2 mg once a day and administered before bed. The titration schedule was administered individually, but within the concept that PER was increased by 2 mg/day no more frequently than once every 2 weeks up to 12 mg/day. The targeted doses varied depending on clinical response and tolerability. The mean maximal dosage of add-on PER was 4.9 ± 2.9 mg (median 4 mg, range: 2-8 mg).
Efficacy
We were able to review 53, 33, and 25 patients who remained on PER at 3, 6, and 12 months, respectively. The retention rates of PER treatment at the different time points of evaluation were 80.3% (3 months), 58.9% (6 months), and 51% (12 months) ( Fig. 2A) . Thirteen patients discontinued PER within the first 3 months, ten between 3 and 6 months, and 1 between 6 and 12 months (Fig. 1) . The reasons for discontinuation of PER were lack of efficacy in 18.2% (n = 12), intolerable adverse effects in 12.1% (n = 8), and aggravation of seizure in 6.1% (n = 4) of patients.
With PER treatment, seizure reduction varied over time with 30.3% (20/66), 37.5% (21/56), and 34.7% (17/49) of patients showing 50% responder rate at the 3-month, 6-month, and the 12-month follow-up, respectively ( Fig. 2A) . The number of patients experiencing complete seizure control (seizure-free for three months before the follow-up visit) increased from five (7.6% at 3 months and 8.9% at 6 months) to seven (26.9%) at 12 months. Five patients reported periods of seizure freedom lasting ≥ 6 months at the final follow-up, and one patient remained seizure-free throughout the 12-month study period. Further information on the demographic characteristics and epilepsy etiology among patients who were seizure-free at any time point of the followup is presented in Table 2 .
The median reductions in seizure frequency in patients who completed 6-and 12-month follow-up was generally above 50%, except patients with 2-mg PER treatment at 6-month follow-up (Fig. 3) . Although statistically nonsignificant, a positive trend was observed between PER daily doses and the median seizure reduction rate at 6-month follow-up, suggesting a higher daily PER dosage reflects greater seizure reduction. However, the correlation was not found in the analysis of the 12-month follow-up data. Regarding the use of concomitant enzyme-inducing antiepileptic drugs, no significant differences were observed concerning the responder rate (Fig. 2B) .
Notably, favorable seizure reduction of ≥50% was observed in four out of five patients (80%) who were classified as having Dravet syndrome (Table 3) , in which complete seizure control was achieved in two patients (40%) and a reduction in seizure frequency of 75-99% was achieved in one patient (10%). Among other patients with known epileptic syndromes (five patients with Lennox-Gastaut syndrome, three patients with juvenile myoclonic epilepsy, and one patient with progressive myoclonic epilepsy) included in present study, there were two responders who were seizure-free: one Lennox-Gastaut syndrome patient evaluated at the 12-month follow-up experienced seizure freedom for 23 weeks, and another patient with intractable juvenile myoclonic epilepsy evaluated at the 6-month follow-up with 12-week seizure freedom (Table 2) .
Safety and tolerability
A total of 25 pediatric patients (37.9%) experienced at least one adverse event (Table 4) , of which irritability (10.6%, n = 7) and skin rash (10.6%, n = 7) were the most common, followed by dizziness (9.1%, n = 6) and somnolence (7.6%, n = 5). Ataxia (4.5%), anxiety (4.5%), headache (3%), poor appetite (3%), aggression (1.5%), and malaise (1.5%) were reported in b5% of patients. Three patients (4.3% of all) reduced the daily PER dose and eight patients (12.1% of all) withdrew from PER treatment because of the adverse events. In four of these eight cases, it was necessary to discontinue PER treatment because of skin rash, which was the most frequent reason to discontinue PER in our study. No serious adverse events (according to the Food and Drug Administration classification) occurred. Most patients (76%, 19/25) experienced these adverse events at treatment initiation or while taking a ≤4-mg daily dose of PER after starting, suggesting that the probability of adverse events did not clearly correlate with the dosage. All observed adverse events were resolved after dose reduction or discontinuation of PER.
Patients taking nonenzyme-inducing antiepileptic drugs in combination with PER exhibited a significantly higher adverse event occurrence (50%) than those who received enzyme-inducing antiepileptic drugs (21.4%) ( Table 4) . A higher frequency of adverse events including skin rash, behavioral adverse events (irritability and anxiety), and somnolence were more likely to be observed in the nonenzyme-inducing antiepileptic drug group than in the enzyme-inducing antiepileptic drug group. However, because of the small sample size of each adverse event, the sensitivity of the Chi-square test was limited and might be a statistical artifact.
Discussion
Although several regulatory studies and observational studies have demonstrated PER to be a safe and effective antiepileptic drug in patients experiencing pharmacoresistant epilepsy, data on the effects of PER in real-world clinical settings in children and adolescents are relatively few. We evaluated the tolerability and efficacy of PER as an add-on therapy for the treatment of pediatric patients with pharmacoresistant epilepsy from a single center in Taiwan, according the latest guidelines of the ILAE. To the best of our knowledge, the present study is the first clinical evaluation of PER treatment in Asian pediatric population with pharmacoresistant epilepsy.
Our retrospective data analysis demonstrated that PER administered as an adjunctive treatment in children and adolescents demonstrated a significant reduction in seizure frequency with an acceptable safety profile, despite the fact that most patients had highly refractory epilepsy. In this real-life population of 66 Taiwanese patients aged ≤ 18 years with highly refractory epilepsy, we demonstrated that 8.9% (5/56) and ADEM: acute disseminated encephalomyelitis; FLE: frontal lobe epilepsy; JME: juvenile myoclonic epilepsy; TLE: temporal lobe epilepsy. 14.3% (7/49) of patients prescribed PER were able to achieve seizure freedom at the end of 6-and 12-month follow-up, respectively, with 37.5% (21/56) and 34.7% (17/49) respectively experiencing a ≥ 50% reduction in seizure frequency. Several observational studies concerning the efficacy and tolerability of PER in pediatric populations have been conducted. A retrospective study of 58 patients aged 2-17 years experiencing various pharmacoresistant epilepsies was first reported by Biró et al.; the 50% responder rate after the first 3 months of therapy was 31% in total, with complete seizure control occurring in 8.6% of patients [29] . The results of an Italian observational multicenter study with an average follow-up of 6.6 months for 62 pediatric patients indicated a 50% responder rate and a 4.8% seizure-free rate [28] . Heyman et al. reported a responder rate of 41.7% and a seizure-free rate of 12.5% in a 24 pediatric patient pool [27] . A similar responder rate was observed in 24 adolescents in a Canadian center over a median treatment duration of 59 weeks [26] ; however, no patients achieved sustained seizure freedom. Recently, a United Kingdom national multicenter observational study in a heterogeneous group of 96 children and adolescents with highly refractory epilepsy who underwent PER treatment reported an overall responder of 18.8% for all seizure types at both 6-and 12-month follow-ups [31] . Our data were generally consistent with previous reports of broadly similar responder and seizure-free rates for the overall core study population.
Enzyme-inducing antiepileptic drugs, such as carbamazepine, oxcarbazepine, and phenytoin, may interfere with the metabolism of PER by accelerating its clearance and reducing the serum drug concentrations [24, 32, 33] . Post-hoc analysis of phase III clinical trials [34] and a retrospective study by Rohracher et al. [35] demonstrated a higher responder rate when subjects were not taking enzyme-inducing antiepileptic drugs in combination with PER. In contrast, an Italian study found that the proportion of responder patients was higher in patients taking enzyme-inducing antiepileptic drugs than in those taking nonenzyme-inducing antiepileptic drugs. However, the majority of prior observational studies have reported no significant difference in the PER responder rate between patients undergoing concomitant treatment [31, [36] [37] [38] , which is consistent with our observations. The diverse results suggest that the effect of concomitant enzyme-inducing antiepileptic drugs on PER may vary in real-world settings.
Although the efficacy of PER treatment in Dravet syndrome was only mentioned sporadically in some reports with a limited number of patients, a clinically significant response was observed in half of them (one patient was seizure-free and one experienced aggravation in [29] ; one patient with ≥75% seizure reduction in [28] ; and lack of efficacy in one [31] ). Notably, our results indicated that PER was conspicuously efficacious in patients with Dravet syndrome, achieving clinically meaningful improvement in four of five patients and even seizure freedom in two patients. Given that current antiepileptic drugs, such as valproate and clobazam, show only modest efficacy in the treatment of Dravet syndrome and rarely provide adequate seizure control [39] , our result suggests that PER may be beneficial as an add-on therapy in this difficult-to-treat population.
Perampanel efficacy has also been assessed in other defined epileptic syndromes. A recent study conducted in 13 Lennox-Gastaut syndrome patients reported that nine patients (69.2%) were responders, and seven patients (53.8%) were improved in cognitive function and/ or behavior [30] . Other studies also indicated a responder of 40-66.6% in a small group of nine patients [28, 29, 31] . In contrast, almost all Lennox-Gastaut syndrome patients in our study had a poor response to PER as adjunctive therapy, with the exception of one patient who achieved seizure freedom at the daily dose of 8 mg by the 12-month follow-up evaluation. Our contradictory result may be due to the small number of patients with this epileptic syndrome, which makes it difficult to draw a conclusion on this issue.
The preclinical efficacy of PER and also other noncompetitive AMPA receptor antagonists were reported in the treatment of mesial temporal lobe epilepsy with or without hippocampal sclerosis [40] . However, to date, there are few data on the use of PER in patients with this type of epileptic syndrome. De Liso et al. reported that two temporal epilepsy adolescent patients with hippocampal sclerosis were seizure-free at the PER dose of 6 and 8 mg, respectively, and without any adverse events. Similarly, in our study, complete seizure control was achieved in a 14-year-old boy with mesial temporal sclerosis in the left during the entire period of treatment. These data support the possibility that PER acting through blocking of AMPA receptors might be an option for the treatment of mesial temporal lobe epilepsy with hippocampal sclerosis.
Our retention rates did not markedly differ from those in various other observational studies: 80.3% after 3 months compared with 83-87%, 58.9% after 6 months compared with 60.1-71%, and 51% after 12 months compared with 47.6-60.4%. Treatment was discontinued because of lack of efficacy/aggravation in 16 (24.2%) and unwanted side [26] [27] [28] [29] 31] . The leading adverse events of PER were irritability followed by skin rash, dizziness, somnolence, ataxia, and anxiety. Although a higher incidence of PER-related behavioral adverse events, including mood swings, irritability, and aggression was previously reported by Biró et al. (24%) , by Datta (50%) and by Swiderska et al.
(N19%) in children and adolescent patients, the appearance of irritability and aggression were only founded in seven patients (10.6%) in our group of patients. One possible explanation may be the lower PER dosage and slow titration rate in this study. In our findings, the occurrence of skin rash was more common than previously reported, leading to PER discontinuation in four patients. It is unclear whether this adverse event is related to the natural differences in race and ethnicity, and further research may be required to address this issue. All adverse events in this study were transient or spontaneously resolved upon PER treatment discontinuation or dose reduction. Notably, patients not taking concomitant enzyme-inducing antiepileptic drugs in this study were more likely to experience adverse events than those taking enzyme-inducing antiepileptic drugs, despite no significant difference being observed in PER efficacy. One possible explanation is that enzyme-inducing antiepileptic drugs reduced serum PER concentrations further, resulting in a lower incidence of adverse events. Increases in PER daily dosage have been suggested to correlate with the reductions in seizure frequency and a higher rate of adverse event occurrence. In contrast, other observational studies [36] [37] [38] 41] indicated no clear relationship between adverse events/efficacy and PER dosage. Indeed, based on our clinical data, we observed a unique group of patients who markedly responded to PER at low dosages, and presumably also low serum concentrations, thus suggesting that the efficacy and tolerability of PER might vary among patients in realworld clinical settings. Another potential explanation is the distinctions in seizure frequency and types, or the use of concomitant antiepileptic drugs that were not conducted in the current study.
The current report has several important limitations. First, this was a retrospective observational study conducted in a relatively small number and heterogeneous group of pediatric patients. Another possible limitation includes the lack of a control group during PER treatment, a lack of information regarding the titration regime of PER, incomplete systematic daily diary collection of seizures and routine adverse event screening, and absence of PER serum level monitoring. Despite the limitations described above, this is the first study demonstrating the efficacy and safety of PER therapy in Asian children and adolescents. Information on the pharmacokinetics in this specific age group and ethnic groups should be further accessed.
Conclusion
This retrospective observational study provides relevant clinical insights on the efficacy and safety of adjunctive PER in Asian children and adolescents. Based on the evidence obtained in this study and from previous studies, we can confirm that PER was effective and exhibited a satisfactory tolerability profile in the treatment of pharmacoresistant epilepsy in pediatric patients and, therefore, has an important role in the treatment armamentarium in clinical practice.
Supplementary data to this article can be found online at https://doi. org/10.1016/j.yebeh.2018.06.033.
